Availability of fixed-dose, child-friendly formulations of first-line tuberculosis drugs in Europe
- Antoni Noguera-Julian1,2,3,4,14,
- Danilo Buonsenso5,6,7,14,
- Lindsay Mckenna8,
- James A. Seddon9,10 and
- Nicole Ritz11,12,13⇑
- 1Infectious Diseases and Systemic Inflammatory Response in Pediatrics, Infectious Diseases Unit, Department of Pediatrics, Sant Joan de Déu Hospital Research Foundation, Barcelona, Spain
- 2Center for Biomedical Network Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain
- 3Department of Pediatrics, University of Barcelona, Barcelona, Spain
- 4Translational Research Network in Pediatric Infectious Diseases (RITIP), Madrid, Spain
- 5Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Ital
- 6Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Rome, Italy
- 7Center for Global Health Research and Studies, Università Cattolica del Sacro Cuore, Rome, Italy
- 8Treatment Action Group, New York, USA
- 9Department of Infectious Diseases, Imperial College, London, UK
- 10Department of Paediatrics and Child Health, Desmond Tutu TB Centre, Stellenbosch University, Cape Town, South Africa
- 11Infectious Diseases Unit and Migrant Health Service, University Children's Hospital Basel, University of Basel, Basel, Switzerland
- 12Department of Biomedicine, University of Basel, Basel, Switzerland
- 13Department of Paediatrics, The University of Melbourne, Parkville, Australia
- 14Both authors share credit for 1st authorship
- Nicole Ritz (nicole.ritz{at}unibas.ch)
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: Dr. Graham has nothing to disclose.
Conflict of interest: Antoni NOGUERA-JULIAN was supported by “Subvencions per a la Intensificació de Facultatius Especialistes” (Departament de Salut de la Generalitat de Catalunya, Programa PERIS 2016-2020) [SLT008/18/00193].
Conflict of interest: Dr. Danilo Buonsenso has nothing to disclose.
Conflict of interest: Dr. Lindsay Mckenna has nothing to disclose.
Conflict of interest: James A. SEDDON is supported by a Clinician Scientist Fellowship jointly funded by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement (MR/R007942/1).
Conflict of interest: Dr. Nicole Ritz has nothing to disclose.
This is a PDF-only article. Please click on the PDF link above to read it.
- Received April 26, 2021.
- Accepted May 21, 2021.
- Copyright ©The authors 2021. For reproduction rights and permissions contact permissions{at}ersnet.org